The DOI matches its Crossref record.
Patient characteristics associated with high-risk methotrexate concentrations and toxicity.
Abstract
PURPOSE: Following high-dose methotrexate (HD-MTX) treatment, delayed MTX elimination is an important problem because it necessitates increased leucovorin rescue and additional hospitalization for hydration and urinary alkalinization. Our purpose was to identify factors associated with high-risk MTX plasma concentrations (defined by plasma concentration > or = 1.0 mumol/L at 42 hours from the start of MTX) and with toxicity. PATIENTS AND METHODS: Variables associated with MTX concentrations and toxicity were assessed in 134 children treated with one to five courses of HD-MTX (900 to 3,700 mg/m2 intravenously [i.v.] over 24 hours for a total of 481 courses) for acute lymphoblastic leukemia (ALL). RESULTS: High-risk MTX concentrations, toxicity (usually mild mucositis), and delay in resuming continuation chemotherapy occurred in 106 (22%), 123 (26%), and 66 (14%) of 481 courses, respectively. Using a mixed effects model for repeated measures, high-risk MTX concentrations were significantly associated with a higher MTX area-under-the-concentration-time curve (AUC), low urine pH, emesis, low MTX clearance, low urine output relative to intake, use of antiemetics during the MTX infusion, and concurrent intrathecal therapy (all p values < .01). Clinical toxicities and delay in resumption of continuation chemotherapy due to myelosuppression were more common in those with high 42-hour MTX concentrations, despite increased leucovorin rescue for all patients with high-risk MTX concentrations. However, with individualized rescue, no patient developed life-threatening toxicity. A more aggressive hydration and alkalinization regimen for subsequent courses reduced the frequency of high-risk MTX concentrations to 7% of courses (13 of 183) (P = .0001), and the frequency of toxicity decreased to 11% of courses (P = .0074). CONCLUSION: This study identified several clinical variables that influence MTX disposition that, when modified, can reduce the frequency of high-risk MTX concentrations and toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Preventing and Managing Toxicities of High-Dose Methotrexate
Howard, S. C., McCormick, J., Pui, C.-H., Buddington, R. K., & Harvey, R. D. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0164 · Cited by 929
Self-citationUnderstanding and Managing Methotrexate Nephrotoxicity
Widemann, B. C., & Adamson, P. C. (2006) · The Oncologist · doi:10.1634/theoncologist.11-6-694 · Cited by 730
Conventional Compared with Individualized Chemotherapy for Childhood Acute Lymphoblastic Leukemia
Evans, W. E., Relling, M. V., Rodman, J. H., Crom, W. R., Boyett, J. M., & Pui, C.-H. (1998) · New England Journal of Medicine · doi:10.1056/nejm199802193380803 · Cited by 492
Self-citationGurney, H. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.9.2590 · Cited by 361
Treviño, L. R., Shimasaki, N., Yang, W., Panetta, J. C., Cheng, C., Pei, D., Chan, D., Sparreboom, A., Giacomini, K. M., Pui, C.-H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.4156 · Cited by 349
Self-citation
Metadata
- Authors
- Relling, M. V., Fairclough, D., Ayers, D., Crom, W. R., Rodman, J. H., Pui, C. H., & Evans, W. E.
- Venue
- Journal of Clinical Oncology
- Published
- 1994-08
- Volume
- 12
- Issue
- 8
- Pages
- 1667-1672
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1899827437
- Cited by
- 215
- References
- 0
- FWCI
- 3.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patient characteristics associated with high-risk methotrexate concentrations and toxicity. https://app.cochat.ai/papers/10.1200/jco.1994.12.8.1667
- The paper
- Relling, M. V., Fairclough, D., Ayers, D., Crom, W. R., Rodman, J. H., Pui, C. H., & Evans, W. E. (1994). Patient characteristics associated with high-risk methotrexate concentrations and toxicity. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1994.12.8.1667
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.